173 related articles for article (PubMed ID: 30198909)
1. NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.
Dunai C; Murphy WJ
J Clin Invest; 2018 Oct; 128(10):4251-4253. PubMed ID: 30198909
[TBL] [Abstract][Full Text] [Related]
2. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
[TBL] [Abstract][Full Text] [Related]
3. NK Cells Respond to Checkpoint Blockade.
Cancer Discov; 2018 Dec; 8(12):1498. PubMed ID: 30352860
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death protein 1 on natural killer cells: fact or fiction?
Cho MM; Quamine AE; Olsen MR; Capitini CM
J Clin Invest; 2020 Jun; 130(6):2816-2819. PubMed ID: 32391808
[TBL] [Abstract][Full Text] [Related]
6. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract][Full Text] [Related]
7. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
[TBL] [Abstract][Full Text] [Related]
8. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
Bai R; Cui J
Front Immunol; 2022; 13():886931. PubMed ID: 35634343
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse.
Huang Y; Chen Z; Jang JH; Baig MS; Bertolet G; Schroeder C; Huang S; Hu Q; Zhao Y; Lewis DE; Qin L; Zhu MX; Liu D
J Allergy Clin Immunol; 2018 Oct; 142(4):1311-1321.e8. PubMed ID: 29679656
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
13. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
14. NK cells limit therapeutic vaccine-induced CD8
Diniz MO; Schurich A; Chinnakannan SK; Duriez M; Stegmann KA; Davies J; Kucykowicz S; Suveizdyte K; Amin OE; Alcock F; Cargill T; Barnes E; Maini MK
Sci Transl Med; 2022 Apr; 14(640):eabi4670. PubMed ID: 35417187
[TBL] [Abstract][Full Text] [Related]
15. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
16. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
[TBL] [Abstract][Full Text] [Related]
19. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.
Del Rio ML; Perez-Simon JA; Rodriguez-Barbosa JI
Front Immunol; 2022; 13():887348. PubMed ID: 35795681
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]